Vectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial Jury
Vectura Group plc (LSE:VEC) ("Vectura" or "the Group") confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s (GSK) Ellipta products. The jury awarded Vectura $89.7m in damages for the period from August 2016 through December 2018, based on a calculation of 3% of US sales of these products. Vectura expects to seek application of the 3% royalty to the sales of the infringing products through the end of the patent term in mid-2021. The jury also found that GSK’s infringement was willful. The willfulness finding gives Vectura the right to seek enhanced damages. GSK has the option to appeal the decision.
James Ward-Lilley, Chief Executive Officer of Vectura, commented:
“Although we regret the need to take a longstanding partner to court, we are pleased with the jury’s verdict which confirms the validity of our intellectual property and the decision to progress this action with GSK. We will provide updates on this matter in due course.”
Background to litigation:
In July 2016, Vectura filed a patent infringement lawsuit against GSK in the United States District Court for the District of Delaware claiming that sales of certain GSK Ellipta products infringed Vectura patents.
Vectura and GSK had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family. These licensed patents expired in July 2016. At this time GSK had the option to license additional patent families under the original agreement but declined to do so, resulting in the filing of the lawsuit by Vectura.
From the outset Vectura has been open to finding a mutually acceptable solution to avoid prolonging the dispute. Those efforts were not fruitful and led to the litigation progressing to a jury trial in April 2019.
Expected news flow for 2019
In the meantime, we continue to focus on executing our strategy and to build on our recently reported strong financial and operational progress. Further expected news flow for 2019 includes:
- VR315 (US) repeat clinical study read-out and resubmission
- VR647 (US) partnering post FDA end of Phase II meeting
- Updated disclosure on new nebulised niche portfolio assets, including potential orphan drug designation
- QVM149 Phase III study completion and submission
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products, and through the development of high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at www.vectura.com
Vectura Group plc
David Ginivan – VP Corporate Communications
+44 (0)7471 352 720
Elizabeth Knowles – VP Investor Relations
+44 (0)7767 160 565
Consilium Strategic Communications
+44 (0)7739 788 014
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 04:00:00 EEST | Tiedote
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta
Audi China President Thomas Owsianski to Keynote at CES Asia 201923.5.2019 23:00:00 EEST | Tiedote
The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019. Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China. Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018. “Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.” Throughout Asia and beyond, technol
ITechLaw Publishes New Book and Opens Global Public Comment Period on Draft Principles for Responsible Artificial Intelligence23.5.2019 22:11:00 EEST | Tiedote
The International Technology Law Association (ITechLaw) has published Responsible AI: A Global Policy Framework, a new book that provides an in-depth review and eight discussion principles that address some of the hottest technology and moral issues of responsible development, deployment and use of artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005752/en/ ITechLaw releases new book, Responsible AI: A Global Policy Framework, and opens public comment period. (Photo: Business Wire) Written by a multi-disciplinary group of 54 technology law experts, industry representatives and researchers from 16 countries, the book offers an actionable framework built on the following principles: Ethical Purpose and Societal Benefit, Accountability, Transparency and Explainability, Fairness and Non-discrimination, Safety and Reliability, Open Data and Fair Competition, Privacy, and AI and Intellectual Property.
Kumulus Vape, the 100% Online E-Cigarette Specialist, Goes Public23.5.2019 19:49:00 EEST | Tiedote
Kumulus Vape (ISIN FR0013419876 – MLVAP ), an online retailer specialised in the sale of electronic cigarettes and related products (devices, e-liquid and accessories), referred collectively as “e-cigarettes”, is pleased to announce the listing of its shares on the Euronext Access™ compartment in Paris by technical admission (Euronext notice PAR_20190523_05573_ACC). First listing will take place on 28 May 2019. This initial public offering - a first in Europe’s e-cigarette space - is a new milestone in the performance trajectory of the Lyon-based company, a pioneer on this market in acceleration phase. Kumulus Vape posted 2018 sales of €6.5 million, up 116% on 2017. Its outlook is highly auspicious, with 96% quarter-on-quarter growth in the first quarter of 2019. Kumulus Vape’s goal is clear: to become one of the French leaders in 100% online e-cigarette retail within three years. AN E-CIGARETTE PIONEER A CATALOGUE OF OVER 6,000 REFERENCES Kumulus Vape is one of the top online French r
Andersen Global Expands UK Locations23.5.2019 16:30:00 EEST | Tiedote
Claritas Tax Limited, a Birmingham, United Kingdom-based collaborating firm of Andersen Global, has opened a new office location in Deansgate, Manchester city center. This means that Andersen Global now has a presence in six locations in the UK through its member firms and collaborating firms. “Now more than ever, it’s important that businesses have easy access to quality advice in the UK’s dynamic political and business environment. The addition of another location in the region adds to our existing capabilities and will allow us to continue providing best-in-class service,” said Mark Vorsatz, Andersen Global Chairman and CEO of Andersen Tax LLC. Founded in 2012, Claritas Tax Limited has a list of clientele from entrepreneurial, privately owned, venture capital, and private equity owned businesses, listed companies and stakeholders. Claritas provides a broad range of tax consulting services, including all aspects of M&A and transactional taxes, R&D and Intellectual Property claims, sh
Mindbreeze Receives Attestation in Accordance with BSI Cloud Requirements23.5.2019 16:11:00 EEST | Tiedote
Mindbreeze receives attestation for its Mindbreeze InSpire SaaS service according to the specifications of the C5 catalogue of requirements (Cloud Computing Compliance Controls Catalogue, abbreviated C5), published by the German Federal Office for Information Security (BSI). The Mindbreeze InSpire SaaS service is professionally operated in Mindbreeze data centers on behalf of the customers. The attestation was issued by KPMG Alpen-Treuhand GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft. “The number of cloud services in the field of data analysis is growing steadily. This makes it all the more essential for customers to take a closer look at the choice of suppliers. C5 provides the regulatorily defined IT security level, which is comparable to the IT basic protection level that is increased by cloud controls,” explains Klaus Schatz, Managing Director of KPMG Advisory GmbH. C5 attestation (ISAE 3000 Report Type 2) is a recognized and authoritative verification for all customer
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme